Search the Newsreel

GODREJAGRO: Q1 FY27 revenue up 10% year-over-year, but margins compressed amid cost and weather headwinds

Cadre Holdings earnings on deck after Q1 miss rattles investors By Investing.com

Cadre Holdings Inc. is set to report its second-quarter results, with analysts expecting a rebound from a disappointing first quarter where the company missed earnings by 50%. Investors will be watching closely to see if Cadre can convert its record $355 million backlog into …

Cooke & Bieler (DFH) discloses 1.87M-share, 5.5% holding in Dream Finders Homes

Cooke & Bieler L.P. has reported a beneficial ownership of 1,870,801 shares of Dream Finders Homes, Inc. Class A common stock, which accounts for 5.5% of the class. The investment firm holds shared voting power over 1,790,855 shares and shared dispositive power over 1,870,801 …

Allard, Allard & Associés Opposes Proposed Andrew Peller Transaction and Intends to Vote Against the Plan of Arrangement

MONTRÉAL, Aug. 5, 2026 /CNW/ -- Allard, Allard & Associés, a significant shareholder of Andrew Peller Limited ("Andrew Peller" or the "Company"), holding 1,705,712 (4.8% of Class A shares and 3.9% of total shares outstanding), today announced its intention to vote against the proposed …

DREAM Unlimited Corp. Class A Revenue Breakdown – TSX:DRM

Earnings Flash (DIR-UN.TO) Dream Industrial REIT Posts Q2 FFO C$0.28 per Share

Godrej Consumer Products Stock And 2 Indian Staples Names Facing Sticky Inflation

Dream Office Real Estate Investment Trust (D-UN) Earnings Preview — What to Watch Before the Report

Godrej Properties shares jump over 4% on positive FY27 outlook, strong residential market

Cadre (CDRE) Earnings Date and Reports 2026

Cadre (NYSE:CDRE) Releases Earnings Results, Beats Estimates By $0.04 EPS

Godrej Agrovet Q1 Results: Animal Nutrition EBIT up 30%, Crop Care down

Dream Industrial REIT Reports Strong Q2 2026 Results and 2.5% Distribution Increase

Whitby, OntarioCalgary, AlbertaEde, NetherlandsOsnabrück, GermanyBerlin (Grossbeeren), GermanySussex, UKManchester, UKManchester (Bredbury), UKValencia, Spain This press release contains forward-looking information that is based upon assumptions and is subject to risks and uncertainties as indicated in the cautionary note contained within this press release. All dollar amounts …

We Like Aldrees Petroleum and Transport Services' (TADAWUL:4200) Earnings For More Than Just Statutory Profit

Godrej Properties Q1 Profit Falls 42% to Rs 349 Cr

Dream Impact Trust Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Godrej Properties uploads earnings call audio for August 4, 2026

Cadre (CDRE) Reports Q2: Everything You Need To Know Ahead Of Earnings

Cadrenal Therapeutics Solidifies Multi-Indication Strategy

Cadrenal Therapeutics is strengthening its multi-indication strategy for CAD-1005, focusing on both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This move follows a competitor's Phase 3 failure in CSA-AKI, highlighting the potential of Cadrenal's 12-LOX inhibitor to address a significant market …

Cadrenal Therapeutics, Inc. SEC Filing (Aug 3, 2026)

This article reports on an SEC filing (Form ARS) by Cadrenal Therapeutics, Inc. (CVKD) on August 3, 2026. The filing has a low impact and neutral sentiment according to AI-generated analysis. The article also provides recent news and other SEC filings for Cadrenal Therapeutics.

Cadrenal expands CAD-1005 development to two indications

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced a dual-indication development strategy for its investigational drug CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). The decision to pursue CSA-AKI follows a competitor's recent Phase 3 trial discontinuation, with Cadrenal estimating the U.S. …

CAD-1005 Phase 2 Data Show >25% Absolute Reduction in Thrombotic Events

Cadrenal Therapeutics announced a consolidated multi-indication strategy for CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), following a competitor's Phase 3 discontinuation. Late-breaking Phase 2 data revealed an absolute reduction in thrombotic events greater than 25% with a favorable …

Cadrenal Therapeutics highlights Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia, eyes CSA-AKI market

Cadrenal Therapeutics is advancing its drug CAD-1005 for heparin-induced thrombocytopenia and cardiac surgery-associated acute kidney injury, supported by positive Phase 2 data presented at ISTH 2026. The drug is positioned as a first-in-class, Phase 3-ready intravenous therapy, especially after a competitor's program failed, and …

Andrew Peller Dividend Analysis 2026: Can the 3.09% Yield Continue Growing?

First Trust Advisors LP Increases Position in Cadre Holdings, Inc. $CDRE

First Trust Advisors LP significantly increased its stake in Cadre Holdings, Inc. (NYSE:CDRE) by 92.6% in the first quarter, now owning 223,898 shares valued at $6.87 million. Other institutional investors also adjusted their positions, while Cadre's CEO, Warren B. Kanders, sold 100,000 shares for …

Rainbow Children's Medicare Limited Just Recorded A 8.0% Revenue Beat: Here's What Analysts Think

Cadrenal Therapeutics Highlights CAD-1005 as Dual-Indication 12-LOX Inhibitor for HIT and CSA-AKI Following Competing Trial Failure

Cadrenal Therapeutics is strategically focusing its investigational drug CAD-1005 for both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This focus comes after a competitor's clinical failure, highlighting the urgent need for treatments targeting cardio-renal injury through 12-lipoxygenase (12-LOX) inhibition. CAD-1005 aims …

Rainbow Childrens Medicare Q1FY26 PAT rises 16% on 33% revenue growth

Price to earnings forward of Andrews Sykes Group plc – LSE:ASY

Rainbow Childrens Medicare revenue surges 33% in Q1FY27

Andrew Peller Limited Class A Revenue Breakdown – TSX:ADW.A

PLCE|Children's Place Inc|Price:2.440|

This article provides a comprehensive stock analysis of Children's Place Inc (PLCE) by TradingKey, assigning it a score of 5.50/10. It highlights weak fundamentals but significant growth potential, fair valuation, and very high institutional ownership. The analysis suggests a downward trend in the medium …

Dream Finders Homes (DFH) Stock Faces Margin Squeeze Despite Low P E

Dream Finders Homes (DFH) stock has seen a significant drop, though its Q2 revenue of US$1.06 billion and a low P/E of 8.7x suggest a complex situation. The main concern is a squeeze on profit margins, with net income roughly halving year-on-year and net …

Dream Industrial Real Estate Investment Trust's Dividend Analysis

This article first appeared on GuruFocus. Assessing the Upcoming Distribution and Long-Term Sustainability Dream Industrial Real Estate Investment Trust (DREUF) recently announced a total dividend of $0.04 per share, with the ex-dividend date set for 2026-07-31. This distribution includes $0.04 per share in cash, …

Dream Finders Homes (NYSE: DFH) posts record Q2 sales but lower profit

Dream Finders Homes (NYSE: DFH) reported record net sales and home closings in Q2 2026, with net sales up 15% and closings up 3%. Despite this, profitability declined significantly, with pre-tax income falling to $37 million from $74 million year-over-year and net income attributable …

Cadre Holdings To Go Ex-Dividend On July 31st, 2026 With 0.1 USD Dividend Per Share

Cadre Holdings (NYSE:CDRE) is scheduled to go ex-dividend on July 31st, 2026. The company will distribute a dividend of $0.1 per share to shareholders. This information is important for investors considering the stock.